We try to keep abreast of the latest news and information relevant to people interested in FCS. Please tell us about any developments we have missed by contacting us
We’ve changed our name!
We’ve been talking about this for a long time now, so we’re really pleased to have…
COVID-19
With the developing corona-virus pandemic, patients with FCS may be wondering about their well-being. In line with…
Glybera gets a second chance
Watch two videos the first is about renewed hopes for Glybera. The second is the story of…
New routes to clinical diagnosis of FCS
This paper explores the way in which clinical results can separate patients with FCS from patients with…
European Athersclerosis Society
Rare dyslipidaemias, from phenotype to genotype to management: a European Atherosclerosis Society task force consensus…
Waylivra /Volanesorsen licenced in Europe by EMA
In February 2019 the European Medicines Agency licenced Waylivra / Volanesorsen as “an adjunct to diet in…
- « Previous
- 1
- 2
- 3
- Next »
